Effectiveness of GLP-1 Receptor Agonists and SGLT-2 Inhibitors Combination Therapy in Type 2 Diabetes: A Real-World Experience
Authors' conclusion
Combination therapy with GLP-1RA and SGLT2-I improves glucose control in a substantial proportion of subjects with T2D. Integrating baseline glycaemic burden with longitudinal metabolic changes may support individualized clinical decision-making.
Study context
- Population
- Adults with T2D treated with combined GLP-1 RA and SGLT2i therapy
- Participants
- 549 adults
- Outcome
- Response: achieving drug-specific expected HbA1c reduction threshold
- Follow-up
- 6-9 months
Methodological detailsreal-world
- Real-world
Main finding
As reported in the abstract
Achieved expected HbA1C reduction (drug-specific thresholds)
Subjects achieving the expected HbA1C reduction
41.9%
Baseline HbA1C, strongest predictor of response: OR per 1% [≈11 mmol/mol] increase
6.60
Observational data: associations, not effects.
Further findings
Predictors of response
- Baseline HbA1c, strongest predictor of response: OR per 1% [≈11 mmol/mol] increase
- 6.60
- Follow-up reductions in FPG and BMI, and increases in HDL-C, also associated with response
Decision curve analysis
- Baseline and extended models gave higher net benefit than treat-all and treat-none strategies
Original publication
Effectiveness of GLP-1 Receptor Agonists and SGLT-2 Inhibitors Combination Therapy in Type 2 Diabetes: A Real-World Experience. Endocr Pract. Published 26 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →